ライフサイエンスコーパス: membranoproliferative glomerulonephritis

1 nemia and severe cryoglobulinemia-associated membranoproliferative glomerulonephritis.

2 recurrent bacterial infections and to type 1 membranoproliferative glomerulonephritis.

3 tis, IgA nephropathy, Alport's syndrome, and membranoproliferative glomerulonephritis.

4 ed with diseases such as IgA nephropathy and membranoproliferative glomerulonephritis.

5 Two patients developed membranoproliferative glomerulonephritis.

6 athological diagnoses on renal biopsies were membranoproliferative glomerulonephritis (23%) followed

7 as been associated with de novo or recurrent membranoproliferative glomerulonephritis and acute trans

8 d-stage renal disease in 12; one patient had membranoproliferative glomerulonephritis and another pat

9 een reported to be typically associated with membranoproliferative glomerulonephritis and less freque

10 This included membranoproliferative glomerulonephritis and relapses in

11 nty-one patients with biopsy-proven, diffuse membranoproliferative glomerulonephritis and significant

12 nephritis, specifically cryoglobulinemic and membranoproliferative glomerulonephritis, and has also b

13 al was seen with recurrent and de novo FSGS, membranoproliferative glomerulonephritis, and HUS/TTP.

14 hey developed splenomegaly, lymphadenopathy, membranoproliferative glomerulonephritis, and lymphocyti

15 nephritides (e.g. Alport's Syndrome, type II membranoproliferative glomerulonephritis, and membranous

16 vere kidney disorders including mesangial or membranoproliferative glomerulonephritis, and/or Henoch

17 gy, whereas overexpression of TSLP induced a membranoproliferative glomerulonephritis, as previously

18 ciated with hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (dense deposit

19 By 6 months of age, ABCA1-/- animals develop membranoproliferative glomerulonephritis due to depositi

20 (FSGS), 57; immunoglobulin A nephritis, 22; membranoproliferative glomerulonephritis (GN), 18; and m

21 enal (membranous glomerulonephritis [GN] and membranoproliferative glomerulonephritis); hematologic (

22 C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are r

23 ulting from other glomerular diseases (FSGS, membranoproliferative glomerulonephritis, IgA nephropath

24 malities in factor H have been implicated in membranoproliferative glomerulonephritis in both humans

25 ch was before the development of spontaneous membranoproliferative glomerulonephritis in some Cfh(-/-

26 in a mouse model of cryoglobulin-associated membranoproliferative glomerulonephritis induced by over

27 riably demonstrating severe neonatal anemia, membranoproliferative glomerulonephritis, liver fibrosis

28 We also evaluated the risk of membranoproliferative glomerulonephritis (MPGN) and cryo

29 Membranoproliferative glomerulonephritis (MPGN) is seen

30 Membranoproliferative glomerulonephritis (MPGN) occurs i

31 Membranoproliferative glomerulonephritis (MPGN) recently

32 opathies, such as IgA nephropathy (IgAN) and membranoproliferative glomerulonephritis (MPGN) remains

33 Membranoproliferative glomerulonephritis (MPGN) type II

34 The same trend appeared with membranoproliferative glomerulonephritis (MPGN), diabeti

35 , a model of cryoglobulinemia and associated membranoproliferative glomerulonephritis (MPGN), in whic

36 TSLPtg) mice, which develop cryoglobulinemic membranoproliferative glomerulonephritis (MPGN).

37 y progressive glomerulonephritis (RPGN), and membranoproliferative glomerulonephritis (MPGN).

38 tic nephropathy, membranous lupus nephritis, membranoproliferative glomerulonephritis, postinfectious

39 Membranoproliferative glomerulonephritis recurred in eig

40 3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced

41 ients had immune-complex glomerulonephritis: membranoproliferative glomerulonephritis type 1 (n = 12)

42 The predominant renal biopsy findings were membranoproliferative glomerulonephritis type 1 or type

43 ceased donor transplants were not present in membranoproliferative glomerulonephritis type I (adjuste

44 Membranoproliferative glomerulonephritis type I [24 of 2

45 reviously published studies of patients with membranoproliferative glomerulonephritis type I are smal

46 allograft for end-stage renal disease due to membranoproliferative glomerulonephritis type I is prese

47 Membranoproliferative glomerulonephritis type II (MPGN I

48 Membranoproliferative glomerulonephritis type II (MPGN I

49 ypical hemolytic uremic syndrome (aHUS), and membranoproliferative glomerulonephritis type II (MPGN2)

50 Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a p

51 eration, atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II, and pa

52 innate immunity, and CFH deficiency leads to membranoproliferative glomerulonephritis type II.

53 nephropathy to 2.09 (95% CI, 1.56-2.78) for membranoproliferative glomerulonephritis type II.

54 plant FSGS was 2.25 (1.6-3.1), P<0.0001, for membranoproliferative glomerulonephritis was 2.37 (1.3-4

55 Renal involvement usually manifests as a membranoproliferative glomerulonephritis with marked mon

56 on with hepatitis C virus (HCV) infection is membranoproliferative glomerulonephritis, with or withou